Hyo Sang Jang

Hyo Sang Jang

Auto-generated profile, based on publicly available information

Hyo Sang Jang

USDA‐ARS, Horticultural Crops Disease and Pest Management Research Unit Corvallis Oregon USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HJHyo Sang Jang
Hyo Sang Jang
SJSubhashis Jana
Subhashis Jana
RBRobert J. Blizzard
Robert J. Blizzard
JMJoseph C. Meeuwsen
Joseph C. Meeuwsen
RMRyan Mehl
Ryan Mehl

26 June 2023 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SJSubhashis Jana
Subhashis Jana
EEEric G. B. Evans
Eric G. B. Evans
HJHyo Sang Jang
Hyo Sang Jang
SZShuyang Zhang
Shuyang Zhang
HZHui Zhang
Hui Zhang
RMRyan Mehl
Ryan Mehl

10 February 2020 in ACS Chemical Biology
Verified
Journal Article
Closed access
HJHyo Sang Jang
Hyo Sang Jang
XGXiaodong Gu
Xiaodong Gu
RCRichard B. Cooley
Richard B. Cooley
JPJoseph J. Porter
Joseph J. Porter
RHRachel L. Henson
Rachel L. Henson
RMRyan Mehl
Ryan Mehl

9 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
EOEdmond F. O’dOnnell
Edmond F. O’dOnnell
HJHyo Sang Jang
Hyo Sang Jang
MPMartin Pearce
Martin Pearce
NKNancy I. Kerkvliet
Nancy I. Kerkvliet
SKSiva Kolluri
Siva Kolluri
The aryl hydrocarbon receptor is required for induction of p21 cip1/waf1 expression and growth inhibition by SU5416 in hepatoma cells

7 June 2023 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
DEDaniel J. Elson
Daniel J. Elson
BNBach D. Nguyen
Bach D. Nguyen
SBSebastian Bernales
Sebastian Bernales
SCSarvajit Chakravarty
Sarvajit Chakravarty
HJHyo Sang Jang
Hyo Sang Jang
SKSiva Kolluri
Siva Kolluri

4 March 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
PKPrasad R. Kopparapu
Prasad R. Kopparapu
MPMartin C. Pearce
Martin C. Pearce
CLChristiane Loehr
Christiane Loehr
CDCathy Duong
Cathy Duong
HJHyo Sang Jang
Hyo Sang Jang
SKSiva Kolluri
Siva Kolluri
Cancer cells exploit the expression of anti-apoptotic protein Bcl-2 to evade apoptosis and develop resistance to therapeutics. High levels of Bcl-2 leads to sequestration of pro-apoptotic proteins causing the apoptotic machinery to halt. In this study, we report discovery of a small molecule, BFC1108 (5-chloro-N-(2-ethoxyphenyl)-2-[(4-methoxybenzyol)amino]benzamide), which targets Bcl-2 and converts it into a pro-apoptotic protein. The apoptotic effect of BFC1108 is not inhibited, but rather potentiated, by Bcl-2 overexpression. BFC1108 induces a conformational change in Bcl-2, resulting in the exposure of its BH3 domain both in vitro and in vivo. BFC1108 suppresses the growth of triple-negative breast cancer xenografts with high Bcl-2 expression and inhibits breast cancer lung metastasis. This study demonstrates a novel approach to targeting Bcl-2 using BFC1108, a small molecule Bcl-2 functional converter that effectively induces apoptosis in Bcl-2–expressing cancers. Significance: We report the identification of a small molecule that exposes the Bcl-2 killer conformation and induces death in Bcl-2–expressing cancer cells. Selective targeting of Bcl-2 and elimination of cancer cells expressing Bcl-2 opens up new therapeutic avenues.